Enanta Pharmaceuticals, Inc. (ENTA): Price and Financial Metrics
Enanta Pharmaceuticals, Inc. (ENTA)
Today's Latest Price: $43.67 USD
Updated Nov 23 4:00pm
Add ENTA to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
See all "A" rated Strong Buy stocks
ENTA Stock Summary
- ENTA's current price/earnings ratio is 369.94, which is higher than 97.72% of US stocks with positive earnings.
- Of note is the ratio of Enanta Pharmaceuticals Inc's sales and general administrative expense to its total operating expenses; just 8.04% of US stocks have a lower such ratio.
- The volatility of Enanta Pharmaceuticals Inc's share price is greater than that of just 3.16% US stocks with at least 200 days of trading history.
- Stocks with similar financial metrics, market capitalization, and price volatility to Enanta Pharmaceuticals Inc are SLAB, STRO, TNAV, EXEL, and SRDX.
- Visit ENTA's SEC page to see the company's official filings. To visit the company's web site, go to www.enanta.com.
ENTA Stock Price Chart Interactive Chart >
ENTA Price/Volume Stats
| Current price | $43.67 | 52-week high | $67.88 |
| Prev. close | $43.57 | 52-week low | $38.40 |
| Day low | $43.24 | Volume | 112,872 |
| Day high | $45.14 | Avg. volume | 188,011 |
| 50-day MA | $45.02 | Dividend yield | N/A |
| 200-day MA | $49.18 | Market Cap | 876.54M |
Enanta Pharmaceuticals, Inc. (ENTA) Company Bio
Enanta Pharmaceuticals is a research and development-focused biotechnology company that uses a chemistry-driven approach and drug discovery capabilities to create small molecule drugs for viral infections and liver diseases. The company was founded in 1995 and is based in Watertown, Massachusetts.
ENTA Price Forecast Based on DCF Valuation
| Current Price | DCF Fair Value Target: | Forecasted Gain: |
| $43.67 | $16.81 | -61% |
The table below illustrates the output of a discounted cash flow forecast using a variety of scenarios for Enanta Pharmaceuticals Inc. To summarize, we found that Enanta Pharmaceuticals Inc ranked in the 26th percentile in terms of potential gain offered. We should note, though, that the most conservative analysis suggests this stock will yield negative results -- and thus may be a potential short opportunity. The most interesting components of our discounted cash flow analysis for Enanta Pharmaceuticals Inc ended up being:
- The business' balance sheet suggests that 1% of the company's capital is sourced from debt; this is greater than merely 5.97% of the free cash flow producing stocks we're observing.
- As a business, Enanta Pharmaceuticals Inc experienced a tax rate of about 33% over the past twelve months; relative to its sector (Healthcare), this tax rate is higher than 91.02% of stocks generating free cash flow.
| Terminal Growth Rate in Free Cash Flow | Return Relative to Current Share Price |
| 0% | -62% |
| 1% | -62% |
| 2% | -61% |
| 3% | -61% |
| 4% | -61% |
| 5% | -60% |
Want more companies with a valuation profile/forecast similar to that of Enanta Pharmaceuticals Inc? See ICUI, WAT, ILMN, XRAY, and A.
Loading social stream, please wait...